Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of ($0.02), $0.04 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $9.01 million versus the consensus estimate of $9.1 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.